Immunovia AB’s initial public offering and listing on Nasdaq Stockholm


Immunovia AB, a mid cap company within the health care sector, is start trading of its shares on the main market of Nasdaq Stockholm.

Founded in 2007, Immunovia is a health care company based in Lund, Sweden, and led by CEO Mats Grahn. The company’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer – earlier and more accurately than previously possible. Its core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is currently performing clinical validation studies for the commercialization of IMMray™ PanCan-d, where the ambition is to become the first blood-based test for early diagnosis of cancer of the pancreas.

Baker McKenzie is acting as legal adviser to Immunovia in connection with the listing on Nasdaq Stockholm, with a team led by Joakim Falkner (picture), alongside Per Blom, Henric Roth, Ian Gulam and Linnea Back.

Involved fees earner: Joakim Falkner – Baker McKenzie; Per Blom – Baker McKenzie; Henric Roth – Baker McKenzie; Ian Gulam – Baker McKenzie; Linnéa Back – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: Immunovia AB;